Latin America Pharmaceuticals and Healthcare Report Q4 2017
|出版日期||內容資訊||英文 39 Pages
|南美的醫藥品、醫療產業 (季度更新) Latin America Pharmaceuticals and Healthcare Report Q4 2017|
|出版日期: 2017年10月18日||內容資訊: 英文 39 Pages||
本報告提供南美的到醫藥品、醫療產業調查分析，到2025年的10年預測為焦點，產業分析，產業預測，產業風險/利潤指數 (RRI) 、市場概要，產業趨勢，各地區的概要等系統性資訊。
BMI View: Macroeconomic and political instability throughout Latin America continue to pose downside risks for drugmaker revenues as access to pharmaceuticals and healthcare remains a concern. Despite this, the Latin America region's high demand for medicines and regulatory advancements will maintain drugmaker interest in the long term.
The Americas region will remain characterised by highly divergent levels of attractiveness for innovative pharmaceutical firms. While North America presents considerable opportunities for the commercialisation of pharmaceuticals, it is vital that companies appreciate the varying levels of investment risks and rewards that are present in the emerging markets of Latin America. BMI's Innovative Pharmaceuticals Risk/Reward Index tool, which provides a globally comparative and numerically based assessment of a market's attractiveness for companies looking to launch a high-value drug, was established to address this.